The roles of dopamine transport inhibition and dopamine release facilitation in wake enhancement and rebound hypersomnolence induced by dopaminergic agents.

@article{Gruner2009TheRO,
  title={The roles of dopamine transport inhibition and dopamine release facilitation in wake enhancement and rebound hypersomnolence induced by dopaminergic agents.},
  author={John A Gruner and Val R Marcy and Yin-Guo Lin and Donna Bozyczko-Coyne and Michael J. Marino and Maciej Gasior},
  journal={Sleep},
  year={2009},
  volume={32 11},
  pages={1425-38}
}
STUDY OBJECTIVE Rebound hypersomnolence (RHS: increased sleep following increased wake) is a limiting side-effect of many wake-promoting agents. In particular, RHS in the first few hours following wake appears to be associated with dopamine (DA)-releasing agents, e.g., amphetamine, but whether it can also be produced by DA transporter (DAT) inhibition alone is unknown. In these studies, DA-releasing and DAT-inhibiting agents and their interaction were systematically examined for their ability… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 17 extracted citations

Lauflumide (NLS-4) Is a New Potent Wake-Promoting Compound

Front. Neurosci. • 2018
View 5 Excerpts
Highly Influenced

Effect of dopamine D4 receptor agonists on sleep architecture in rats

Progress in Neuro-Psychopharmacology and Biological Psychiatry • 2015
View 1 Excerpt

Interactions between bupropion and 3,4-methylenedioxymethamphetamine in healthy subjects.

The Journal of pharmacology and experimental therapeutics • 2015
View 2 Excerpts

Similar Papers

Loading similar papers…